GlassScriptPhysician profile
Paxton J Longwell
NPI 1518074095
$1,691.20
in general payments reported to CMS, 2019-2025
24 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $242 · 2021: $262 · 2022: $96.54 · 2023: $226 · 2024: $302 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $497.45 | 2020-2025 | |
| Abbvie INC. | $195.80 | 2021-2024 | |
| Ge Healthcare | $115.45 | 2019-2024 | |
| Allergan, INC. | $108.50 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $99.84 | 2019-2021 | |
| Biogen, INC. | $89.92 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $84.44 | 2019 | |
| Insightec,INC | $58.94 | 2024-2025 | Exablate |
| Emd Serono, INC. | $58.43 | 2019-2021 | |
| Ucb, INC. | $53.08 | 2019 | |
| Mdd US Operations, LLC | $41.29 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.04 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $27.99 | 2024 | |
| Inspire Medical Systems, INC. | $24.86 | 2023 | Inspire |
| Amgen INC. | $23.87 | 2023 | Aimovig |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $21.03 | 2021 | |
| Acadia Pharmaceuticals INC | $20.99 | 2023 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $20.28 | 2020 | |
| Octapharma USA, INC. | $20.00 | 2024 | Panzyga |
| Medtronic, INC. | $19.99 | 2024 | Percept PC Brainsense |
| Lilly USA, LLC | $19.53 | 2019 | |
| Tg Therapeutics, INC. | $18.46 | 2025 | |
| Livanova USA, INC. | $17.20 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paxton Longwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.